Brokerages predict that Ritter Pharmaceuticals Inc (NASDAQ:RTTR) will post earnings of ($0.37) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Ritter Pharmaceuticals’ earnings. Ritter Pharmaceuticals posted earnings of ($0.83) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 55.4%. The business is expected to issue its next quarterly earnings report on Friday, November 8th.
According to Zacks, analysts expect that Ritter Pharmaceuticals will report full-year earnings of ($1.30) per share for the current year. For the next fiscal year, analysts anticipate that the company will post earnings of ($0.55) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Ritter Pharmaceuticals.
Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.18.
A hedge fund recently bought a new stake in Ritter Pharmaceuticals stock. Virtu Financial LLC bought a new stake in Ritter Pharmaceuticals Inc (NASDAQ:RTTR) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 52,426 shares of the biotechnology company’s stock, valued at approximately $46,000. Virtu Financial LLC owned 0.91% of Ritter Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 6.09% of the stock is owned by institutional investors.
Shares of NASDAQ:RTTR traded up $0.02 during midday trading on Friday, reaching $0.92. 59,663 shares of the company’s stock traded hands, compared to its average volume of 407,384. The company has a market cap of $8.65 million, a price-to-earnings ratio of -0.25 and a beta of 1.27. Ritter Pharmaceuticals has a one year low of $0.47 and a one year high of $2.56. The stock has a 50 day moving average of $1.00 and a 200 day moving average of $0.87.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.
Recommended Story: How do analysts define an oversold condition?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.